PerkinElmer Invests in Carterra, the Leader in Label-Free High Throughput Antibody Screening and Characterization
PerkinElmer Invests in Carterra, the Leader in Label-Free High Throughput Antibody Screening and Characterization
12/14/20, 1:04 PM
Location
salt lake cityIndustry
pharmaceutical
biotechnology
Carterra, Inc., the world leader in label-free high throughput antibody screening and characterization, today announced that they have closed on a round of equity financing led by PerkinElmer, Inc. Current Carterra investors Telegraph Hill Partners and Ballast Point Ventures also participated in the financing round.
Company Info
Location
salt lake city, utah, united states
Additional Info
Carterra® is privately held and is the leading provider of high-throughput technologies designed to accelerate and improve the discovery of novel therapeutic candidates. Carterra’s LSA® instrument, software, and consumables for biotherapeutic discovery and characterization deliver up to 100 times the throughput of existing platforms in 10% of the time while using only 1% of the sample required by other systems. The LSA combines patented microfluidics technology with real-time high-throughput Surface Plasmon Resonance (HT-SPR) and industry-leading data analysis and visualization software to revolutionize mAb screening. The new LSA-XT provides enhanced optics to enable additional applications in biotherapeutic discovery and characterization.